Amarin Corp Plc (AMRN)

[Jasbg]

A sensible 'lets calm down' input borrowed from Yahoo:

Thanks to george.

george - 2 days ago

Needless to say all of us sLongs are shocked at the results of the appellate court decision. We will just have to be patient, and those who understand the potential of Vascepa / EPA, and hang in there will be rewarded. Amrn sales will continue to grow at double digit each qtr. in-spite of generics, and Amrn has stated they may also enter the generic market if needed.

The Addressable market for Vascepa, with or without generics, is just huge. The Statin market alone is $1 trillion worldwide... this includes generics as well as Branded. And keep mind Vascepa is to be taken with Statins, unless it’s prescribed for those with type 2 diabetes, which is another huge market.
If within 5-7 years only 10% of everyone on statins is taking the Vascepa or EPA in the generic form, it will be 100 billion dollar market ... now add to that all those with type 2 diabetes, and all those with two or more risk factors for heart disease, as that is what the FDA approved for Vascepa. (cut that in half and you still have a 50 billion dollar market for this drug). Amrn is in first position to capture the larger share of this market.

Amrn will dominate the U.S. market for at least 1-3 more years regardless of generic-competition.
And, they will achieve approx. 1-2 billion in sales. During this time frame. And that’s just in The U.S.
The Worst case Is now priced in to the stock and I believe we at, or close to the bottom. And, we still have European market Asia, and Canada. Where patents granted cannot be challenged . And a Final appeal to the Supreme Court is still on the table.

And let’s not forget the evaporate study results which have been lost shuffled during this showed a 17% reduction in arterial plaque . The significance of this cannot be overstated !

The news of this evaporate study, which was just released last Saturday has yet to be digested by the market and medical community, and it was lost in the shuffle as the market was more focused on the Patent appeal, which followed 2 days after the evaporate results were announced.

The judicial system is really screwed up...how they could possibly rule against The U.S. patent office is beyond belief. How can some low level district judge pretend to know more than the U.S. patent office about the science and the “obviousness” issue, which is a key test for all patent applications.

Amrn spent spent $500 million and 10 years in development and research when all others failed, including some major pharmaceutical companies, and then have a district judge say that this was obvious ! Amren will most likely appeal to the Supreme Court, thus delaying the potential launch of generics, as generics would risk losing all their profits To AMRN should they launch and then lose on final appeal . I am still hopeful that at this point Amaren will seek a partnership deal with Big Pharma, which would accelerate their distribution and growth, and may also help with an appeal to the Supreme Court, as big Pharma has the guns to pursue this erroneous appellate court decision. These judges are all either politically motivated or simply don’t care to understand the real issues in this case or the rights under the Patents. In my opinion, this setback simply means we will be rewarded later than sooner.

Jasbg

PS. And also george calls for the need for BP - to get things rolling for real